Pacific Edge Limited (PFGTF)
| Market Cap | 186.22M +270.2% |
| Revenue (ttm) | 7.44M -42.8% |
| Net Income | -20.44M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.1938 |
| Previous Close | 0.1800 |
| Day's Range | 0.1938 - 0.1938 |
| 52-Week Range | 0.0678 - 0.2327 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 24, 2026 |
About Pacific Edge
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urologi... [Read more]
Financial Performance
In fiscal year 2026, Pacific Edge's revenue was 13.01 million, a decrease of -42.80% compared to the previous year's 22.75 million. Losses were -35.78 million, 19.5% more than in 2025.
Financial numbers in NZD Financial StatementsNews
Pacific Edge Earnings Call Transcript: H2 2026
FY 2026 saw revenue fall 47% and a net loss of NZD 35.8 million due to Medicare non-coverage, but recent draft Medicare coverage for Triage and Triage Plus, a successful NZD 25.4 million capital raise, and APAC growth position the business for recovery and future profitability.
Pacific Edge Slides: H2 2026
Pacific Edge has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 24, 2026.
Pacific Edge Earnings release: H2 2026
Pacific Edge released its H2 2026 earnings on May 24, 2026, summarizing the period's financial results.
Pacific Edge Annual report: H2 2026
Pacific Edge has published its H2 2026 annual report on May 24, 2026.
Pacific Edge Annual report: H2 2026
Pacific Edge has published its H2 2026 annual report on May 24, 2026.
Pacific Edge Transcript: Investor update
Draft Medicare coverage for key tests is expected before September 2026, with claim-by-claim reimbursement targeted to drive interim revenue. Cash burn has been reduced, a NZD 24 million capital raise is underway, and commercial payer adoption is advancing, supported by strong clinical evidence and new pilot studies.
Pacific Edge Slides: Investor update
Pacific Edge has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.
Pacific Edge Press release: Investor update
Pacific Edge issued a press release on May 10, 2026, disclosing material business information to investors.
Pacific Edge Slides: Investor presentation
Pacific Edge has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Pacific Edge Earnings Call Transcript: H1 2026
Revenue and test volumes declined sharply due to Medicare non-coverage, resulting in a $19.1M net loss and increased reliance on cash reserves. Strategic milestones include a price increase for Triage Plus and a key policy review by Novitas in early 2026, with recovery dependent on appeal outcomes.
Pacific Edge Quarterly report: H1 2026
Pacific Edge has published its H1 2026 quarterly earnings report on November 24, 2025.
Pacific Edge Slides: H1 2026
Pacific Edge has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 24, 2025.
Pacific Edge Earnings release: H1 2026
Pacific Edge released its H1 2026 earnings on November 24, 2025, summarizing the period's financial results.